APTV
AptivDAI scenario view
RankAlpha Sentiment CodexAI sentiment snapshot
AI commentary
Primary-source flow over the last two months has been busy but mostly corporate-transaction driven: the spin-off, debt tender and scheduled May 5 print keep headline buzz elevated, yet none of that by itself resolves the key question of what New Aptiv can earn post-spin. Social coverage was not provided in the packet, and no reliable post-print analyst revision set was available here, so confidence should stay moderate rather than aggressive.
Evidence flagged
peer set is too generic or lacks enough direct operating comparators
AI events
Aptiv approved the Versigent spin-off with a March 17, 2026 record date and April 1, 2026 distribution date, with holders receiving one Versigent share for every three Aptiv shares; the market now has to re-underwrite New Aptiv on a standalone basis [#IR-2026-03-05].
Aptiv said it will release Q1 2026 results on May 5, 2026 before market open and report them as Total Aptiv including the EDS business as a segment, making this the first near-term checkpoint on demand, margin and separation execution [#IR-2026-03-31].
Aptiv's February outlook framed New Aptiv at $12.8-$13.2 billion of 2026 sales, 18.6% adjusted EBITDA margin and $200-$300 million of free cash flow, but those pro forma targets still need confirmation through post-spin execution and the May 5 update [#IR-2026-02-02].
Recommendation
No formal recommendation provided.

